hotspot -WSS

hotspot

author：knowledge 2025-08-23 08:52:58 - browse：51

Multiple syringes in a vial -- Pharma coverage from STAT — Adobe

Roughly two million Americans are expected to receive a cancer diagnosis this year. Some members of this already vulnerable group will wind up facing what physician Andrew Schuman recently called “a tragedy happening in slow motion” — an ongoing, nationwide shortage of critical oncology drugs that routinely save or extend the lives of children and adults.

Speaking at a March 22 Senate hearing on drug shortages, Schuman, a head and neck surgeon at the U.S. Department of Veterans Affairs, described the agonizing decisions that doctors must make when critical medicines are in short supply. “Should our limited vials go to an older woman who was just diagnosed with lung cancer? To a young man who had already been successfully taking it for his testicular cancer? Or a baby with neuroblastoma?” he asked. “As a doctor who has devoted my life to fighting cancer, it is hard to express how horrible it is to face this kind of tragedy.”

The dilemmas caused by cancer drug shortages are unfortunately nothing new. In the past decade alone, eight of the 10 drugs most commonly used to treat acute lymphoblastic leukemia, the most common kind of childhood cancer type of leukemia, have been temporarily unavailable. The problem has been getting worse: Nationwide shortages of critical drugs increased nearly 30% in 2022, soaring to their highest level in nearly five years, according to a report released by the Senate Homeland Security and Governmental Affairs Committee for the hearing. Oncology drugs currently in short supply include methotrexate, which treats breast and soft tissue cancers; cisplatin, which treats testicular, ovarian, bladder, head and neck, lung, and cervical cancers; fluorouracil, which treats skin cancer; Pluvicto, for prostate cancer; and the injectable bacillus Calmette-Guérin, for bladder cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Prime Medicine says its gene editing passes test in monkeys

explore

WSS

PhRMA lawsuit over Medicare drug price negotiation tossed

Readout LOUD podcast: How biotech is using artificial intelligence

Readout LOUD podcast: How biotech is using artificial intelligence

Brain injuries and the importance of a second opinion

Doctors' information doesn't help them choose wisely when sick

Readout LOUD podcast: How biotech is using artificial intelligence

leisure time

hotspot

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What should King Charles tell the public about his cancer?

After affirmative action ruling, medical educators look to 'holistic review'

The health care issue Democrats can’t solve: hospital reform

Drug repurposing or repositioning? The language matters

Medicare threatens to cut off funding for HCA's Mission hospital

Moonlake's readout produced a cash windfall. Risks remain

For Medicare Advantage, Democrats want stronger protections around AI

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout LOUD podcast: How biotech is using artificial intelligence

knowledge

Gene therapy’s promise and the high cost of hope

What should King Charles tell the public about his cancer?

Kidney transplant patients stopped immunosuppressants in trial

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Gilead might be held responsible for not developing a drug

Brain injuries and the importance of a second opinion

entertainment

explore

entertainment

focus